Invus Public Equities, L.P.
Invus Public Equities, L.P.'s purchase track record
How the stock did after each of Invus Public Equities, L.P.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/12/2023 | SRRK | $15.09M | +97.3% | +75.8% | +19.5% |
| 4/28/2023 | SRRK | $203K | +9.7% | +61.6% | -1.3% |
| 2/17/2023 | CBIO | $1.22M | +5.3% | -16.5% | +7.1% |
| 2/9/2023 | CBIO | $2.72M | -46.6% | -50.0% | +9.5% |
| 1/5/2023 | SRRK | $455K | -16.5% | -20.2% | +15.8% |
| 10/25/2022 | SRRK | $1.05M | +57.0% | -8.5% | +5.5% |
| 10/3/2022 | SRRK | $760K | +35.1% | +19.0% | +12.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
Transaction History
| SRRK | ▼ Sell | Open Market | 1,600,000 | $66.6M | 12/10/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 149 | $6K | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 208,272 | $7.8M | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 43,887 | $1.7M | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 126,442 | $5.0M | 11/25/2024 | View on chart |
| SRRK | ▼ Sell | Open Market | 30,683 | $1.2M | 11/25/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 260,873 | $50K | 8/8/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 61,488 | $11K | 8/7/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 55,732 | $10K | 8/6/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 164,523 | $31K | 8/5/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 286,200 | $57K | 8/2/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 63,564 | $14K | 8/1/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 756,835 | $167K | 7/30/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 363,949 | $86K | 7/29/2024 | View on chart |
| CBIO | ▼ Sell | Open Market | 258,335 | $62K | 7/26/2024 | View on chart |
| SRRK | ▲ Buy | Open Market | 2,189,781 | $15.0M | 10/12/2023 | View on chart |
| SRRK | ▲ Buy | Open Market | 10,150 | $87K | 10/12/2023 | View on chart |
| SRRK | ▲ Buy | Open Market | 31,557 | $203K | 4/28/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 100,000 | $170K | 2/24/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 200,000 | $351K | 2/23/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 150,000 | $269K | 2/22/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 50,000 | $93K | 2/21/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 200,000 | $341K | 2/17/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 315,266 | $531K | 2/16/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 1,000,000 | $2.2M | 2/15/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 11,451 | $37K | 2/9/2023 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,094 | $10K | 1/9/2023 | View on chart |
| SRRK | ▲ Buy | Open Market | 48,774 | $455K | 1/5/2023 | View on chart |
| SRRK | ▲ Buy | Open Market | 130,265 | $1.0M | 10/25/2022 | View on chart |
| SRRK | ▲ Buy | Open Market | 66,000 | $521K | 10/4/2022 | View on chart |
| SRRK | ▲ Buy | Open Market | 33,971 | $239K | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.